Literature DB >> 35107303

Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.

Marta Hernández-García1,2,3,4, Juan Antonio Castillo-Polo1,2,4, Desirèe Gijón Cordero1,2,4, Blanca Pérez-Viso1,2,4, María García-Castillo1,2,4, Javier Saez de la Fuente5, María Isabel Morosini1,2,4, Rafael Cantón1,2,3,4, Patricia Ruiz-Garbajosa1,2,3,4.   

Abstract

The emergence of Klebsiella pneumoniae isolates carrying novel blaKPC variants conferring ceftazidime-avibactam (CAZ/AVI) resistance is being increasingly reported. We evaluated the accuracy of phenotypic methods commonly used in routine clinical laboratories in the detection of novel K. pneumoniae carbapenemase (KPC) enzymes. Additionally, we characterized by whole-genome sequencing (WGS) the KPC-ST307-K. pneumoniae isolates recovered in our hospital before and after CAZ/AVI therapy. Rectal colonization or infection by carbapenem-resistant KPC-3 K. pneumoniae isolates (imipenem MIC, 16 mg/L; meropenem MIC, 8 to >16 mg/L) and CAZ/AVI-susceptible isolates (CAZ/AVI MIC, 1 to 2 mg/L) were first detected in three intensive care unit (ICU) patients admitted between March 2020 and July 2020. KPC K. pneumoniae isolates with increased CAZ/AVI MICs (8 to 32 mg/L) and carbapenem susceptibility (imipenem and meropenem MIC, <1 mg/L) were recovered within 6 to 24 days after CAZ/AVI treatment. WGS confirmed that all KPC K. pneumoniae isolates belonged to the sequence type 307 (ST307) high-risk clone and carried identical antimicrobial resistance genes and virulence factors. The presence of the novel blaKPC-46, blaKPC-66, and blaKPC-92 genes was confirmed in the K. pneumoniae isolates with increased CAZ/AVI MICs and restored carbapenem activity. KPC production was confirmed by immunochromatography, the eazyplex Superbug CRE system, and the Xpert Carba-R assay in all KPC K. pneumoniae isolates, but not in any isolate using chromogenic agar plates for carbapenemase producers (ChromID-CARBA), the KPC/MBL/OXA-48 Confirm kit, and the β-CARBA test. Nevertheless, all grew in chromogenic agar plates for extended-spectrum β-lactamase (ESBL) producers (ChromID-ESBL). We report the failure of the most common phenotypic methods used for the detection of novel KPC carbapenemases but not of rapid molecular or immunochromatography assays, thus highlighting their relevance in microbiology laboratories.

Entities:  

Keywords:  KPC-3-ST307-K. pneumoniae high-risk clone; carbapenemase phenotypic detection; ceftazidime-avibactam susceptibility; novel blaKPC variants

Mesh:

Substances:

Year:  2022        PMID: 35107303      PMCID: PMC8925889          DOI: 10.1128/jcm.02245-21

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  34 in total

1.  Evaluation of the eazyplex® SuperBug CRE system for rapid detection of carbapenemases and ESBLs in clinical Enterobacteriaceae isolates recovered at two Spanish hospitals.

Authors:  Sergio García-Fernández; María-Isabel Morosini; Francesc Marco; Desirèe Gijón; Andrea Vergara; Jordi Vila; Patricia Ruiz-Garbajosa; Rafael Cantón
Journal:  J Antimicrob Chemother       Date:  2014-11-26       Impact factor: 5.790

2.  Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Authors:  Gary Wu; Teena Abraham; Spencer Lee
Journal:  Clin Infect Dis       Date:  2016-07-17       Impact factor: 9.079

3.  Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.

Authors:  Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

4.  In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain.

Authors:  Marta Hernández-García; María García-Castillo; Patricia Ruiz-Garbajosa; Germán Bou; María Siller-Ruiz; Cristina Pitart; Irene Gracia-Ahufinger; Xavier Mulet; Álvaro Pascual; Nuria Tormo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.938

5.  In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing.

Authors:  Alessandra Carattoli; Ea Zankari; Aurora García-Fernández; Mette Voldby Larsen; Ole Lund; Laura Villa; Frank Møller Aarestrup; Henrik Hasman
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

6.  Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain.

Authors:  Azita Leavitt; Inna Chmelnitsky; Itzhak Ofek; Yehuda Carmeli; Shiri Navon-Venezia
Journal:  J Antimicrob Chemother       Date:  2009-11-24       Impact factor: 5.790

Review 7.  Emerging Antimicrobial-Resistant High-Risk Klebsiella pneumoniae Clones ST307 and ST147.

Authors:  Gisele Peirano; Liang Chen; Barry N Kreiswirth; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

8.  KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.

Authors:  Laurent Poirel; Xavier Vuillemin; Mario Juhas; Amandine Masseron; Ursina Bechtel-Grosch; Simon Tiziani; Stefano Mancini; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

9.  Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Liang Chen; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Open Forum Infect Dis       Date:  2017-07-01       Impact factor: 3.835

10.  Emergence of the New KPC-49 Variant Conferring an ESBL Phenotype with Resistance to Ceftazidime-Avibactam in the ST131-H30R1 Escherichia coli High-Risk Clone.

Authors:  Marta Hernández-García; Javier Sánchez-López; Laura Martínez-García; Federico Becerra-Aparicio; María Isabel Morosini; Patricia Ruiz-Garbajosa; Rafael Cantón
Journal:  Pathogens       Date:  2021-01-14
View more
  1 in total

1.  Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate.

Authors:  Paolo Gaibani; Gabriele Bianco; Stefano Amadesi; Matteo Boattini; Simone Ambretti; Cristina Costa
Journal:  Antimicrob Agents Chemother       Date:  2022-04-13       Impact factor: 5.938

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.